Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naïve HIV-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3101-3106

  Rizk, Matthew L ^a   Hang, Yaming ^a   Luo, Wen Lin ^a   Su, Jing ^a   Zhao, Jing ^a   Campbell, Havilland ^a   Nguyen, Bach Yen T ^a   Sklar, Peter ^a   Eron, Joseph J ^b   Wenninga, Larissa ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; RALTEGRAVIR; TENOFOVIR; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSAGE SCHEDULE COMPARISON; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84861117834     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06417-11     Document Type: Article

References (22)

1. Arab-Alameddine M, et al. 2011. Population pharmacokinetics of raltegravir in HIV positive and healthy subjects, abstr. O15. Abstr. 12th Int. Workshop Clin. Pharmacol. HIV Ther., Miama, FL, 13-15 April 2011.
2. Brainard DM, et al. 2011. Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics. J. Clin. Pharmacol. 51:422-427.
3. Brainard DM, Wenning LA, Stone JA, Wagner JA, Iwamoto M. 2011. Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor. J. Clin. Pharmacol. 51:1376-1402.
4. Cooper DA, et al. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 359:355-365.
5. DeJesus E, et al. 2006. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naïve and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43:1-5. (Pubitemid 44306480)
6. Eron JJ, Jr, et al. 2011. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect. Dis. 11:907-915.
7. Gatell JM, et al. 2010. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J. Acquir. Immune Defic. Syndr. 53:456-463.
8. Grinsztejn B, et al. 2007. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 369:1261-1269. (Pubitemid 46553846)
9. Iwamoto M, et al. 2008. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin. Pharmacol. Ther. 83:293-299.
10. Lennox JL, et al. 2009. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomized controlled trial. Lancet 374:796-806.
11. Lennox JL, et al. 2010. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 55:39-48.
12. Markowitz M, et al. 2006. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43:509-515. (Pubitemid 44885615)
13. Markowitz M, et al. 2007. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J. Acquir. Immune Defic. Syndr. 46:125-133. (Pubitemid 47482607)
14. Markowitz M, et al. 2009. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J. Acquir. Immune Defic. Syndr. 52:350-356.
15. Merck & Co., Inc. 2009. Isentress (raltegravir) prescribing information. Merck & Co., Inc., Whitehouse Station, NJ.
16. Merschman SA, Vallano PT, Wenning LA, Matuszewski BK, Woolf EJ. 2007. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 857:15-24. (Pubitemid 47362852)
17. Rockstroh JK, et al. 2011. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin. Infect. Dis. 53:807-816.
18. Song I, et al. 2009. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients, abstr. WEPEB250. Abstr. Int. AIDS Soc. 5th Conf. HIV Pathog. Treatment Prev. International AIDS Society, Geneva, Switzerland.
19. Steigbigel RT, et al. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359:339-354.
20. Steigbigel RT, et al. 2010. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCH-MRK 1 and 2 phase III trials. Clin. Infect. Dis. 50:605-612.
21. Wang L, et al. 2011. Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers. Antimicrob. Agents Chemother. 55:4090-4095.
22. Wenning L, et al. 2008. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase II and III studies in treatment experienced HIV-infected patients, abstr. O21. Abstr. 9th Int. Workshop Clin. Pharmacol. HIV Ther., New Orleans, LA, 7 to 9 April 2008.